Table 2 Relationship between MRPL13 expression and clinicopathological parameters of ovarian epithelial malignant tumors.

From: MRPL13 enhances mitochondrial function and promotes tumor progression in ovarian cancer by inhibiting mPTP opening via SLC25A6

Groups

Cases

Low

High

Positive rate (%)

P value

High positive rate (%)

P value

-

+

++

+++

Age

      

0.439

 

0.754

<55

58

5

11

17

25

91.38

 

72.41

 

≥55

56

2

12

23

19

96.43

 

75.00

 

FIGO stage

      

0.431

 

0.025*

I-II

45

4

13

15

13

91.11

 

62.22

 

III-IV

69

3

10

25

31

95.65

 

81.16

 

Differentiation

      

0.714

 

0.336

Well-moderate

56

4

13

17

22

92.86

 

69.64

 

Poor

58

3

10

23

22

94.83

 

77.59

 

Lymphatic metastasis

     

0.350

 

0.815

No

72

3

16

26

27

95.83

 

73.61

 

Yes

29

3

4

11

11

89.66

 

75.86

 

Unknown

13

1

3

3

6

92.31

 

69.23

 

Pathological type

      

0.723

 

0.239

Serous

71

5

13

30

23

92.96

 

74.65

 

Mucinous

10

0

4

2

4

100.00

 

60.00

 

Endometrioid

20

2

5

5

8

90.00

 

65.00

 

Clear cell carcinoma

13

0

1

3

9

100.00

 

92.31

 
Back to article page